Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

86.64 -0.14 (-0.16%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,601,359
Open 87.00
Bid (Size) 86.61 (6)
Ask (Size) 87.25 (10)
Prev. Close 86.78
Today's Range 86.23 - 87.42
52wk Range 71.50 - 95.72
Shares Outstanding 2,531,374,696
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
From Merck & Co., Inc.
Via Business Wire
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29
Reuters 
Via Benzinga

Performance

YTD
+12.71%
+12.71%
1 Month
-0.28%
-0.28%
3 Month
-4.97%
-4.97%
6 Month
+5.59%
+5.59%
1 Year
+15.38%
+15.38%

More News

Read More
Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China
Via Benzinga
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
From Merck & Co., Inc.
Via Business Wire
7 Blue-Chip Sleeper Stocks to Buy Before Wall Street Wakes Up
Via InvestorPlace
Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer
Via Benzinga
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
7 Dow Sleeper Stocks to Buy Before Wall Street Wakes Up
Via InvestorPlace
Can Healthcare Stocks Continue To Outperform?
Via Talk Markets
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Via Talk Markets
Costco Down After Earnings as Analysts Fret About Company Facing Higher Costs
Via Benzinga
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Via Benzinga
Renewed Recession Fears Weigh After Rate Hike
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs
Via Investor's Business Daily
Looking At Merck & Co's Recent Whale Trades
Via Benzinga
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Via Benzinga
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
From Merck & Co., Inc. Merck
Via Business Wire
Why Is Evaxion Biotech (EVAX) Stock Up Today?
Via InvestorPlace
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
Via InvestorPlace
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Via Benzinga
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.